Nuvalent (NUVL) Interest & Investment Income (2021 - 2026)
Nuvalent's (NUVL) quarterly Interest & Investment Income came in at $12.9 million in Q1 2026, up 8.68% YoY from $11.8 million in Q1 2025, and up 10.94% on a QoQ basis from $11.6 million in Q4 2025.
Analysis
Nuvalent (NUVL) Interest & Investment Income (2021 - 2026) Analysis & Trends
Nuvalent (NUVL) has 5 years of Interest & Investment Income data on file, last reported at $12.9 million in Q1 2026.
- Quarterly Interest & Investment Income rose 8.68% year-over-year to $12.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.8 million (up 9.67% YoY) and the FY2025 annual result came in at $44.8 million, up 16.65% from the prior year.
- Interest & Investment Income grew to $12.9 million in Q1 2026, from $11.6 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $13.1 million in Q4 2024 to a low of $139000.0 in Q1 2022.
- A 5-year average of $7.3 million and a median of $8.2 million in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2023 — Interest & Investment Income soared 3510.07% — and 2025, when it decreased 11.5%.
- Tracing NUVL's Interest & Investment Income over 5 years: stood at $3.2 million in 2022, then surged by 156.82% to $8.2 million in 2023, then surged by 60.3% to $13.1 million in 2024, then slipped by 11.5% to $11.6 million in 2025, then climbed by 10.94% to $12.9 million in 2026.
- The last three Interest & Investment Income figures came in at $12.9 million (Q1 2026), $11.6 million (Q4 2025), and $10.2 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 12.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 12.90 Mn |
| Dec 31, 2025 | 11.60 Mn |
| Sep 30, 2025 | 10.20 Mn |
| Jun 30, 2025 | 11.12 Mn |
| Mar 31, 2025 | 11.84 Mn |
| Dec 31, 2024 | 13.10 Mn |
| Sep 30, 2024 | 8.70 Mn |
| Jun 30, 2024 | 8.15 Mn |
| Mar 31, 2024 | 8.50 Mn |
| Dec 31, 2023 | 8.17 Mn |
| Sep 30, 2023 | 5.14 Mn |
| Jun 30, 2023 | 4.97 Mn |
| Mar 31, 2023 | 5.02 Mn |
| Dec 31, 2022 | 3.22 Mn |
| Sep 30, 2022 | 672,000.00 |
| Jun 30, 2022 | 267,000.00 |
| Mar 31, 2022 | 139,000.00 |
| Dec 31, 2021 | 114,000.00 |